Hypoglycemia engenders an autonomically mediated counterregulatory (CR)-response that stimulates endogenous glucose production to maintain concentrations within an appropriate physiological range. Although the involvement of the brain in preserving normoglycemia has been established, the neurocircuitry underlying centrally mediated CR-responses remains unclear. Here we demonstrate that lateral parabrachial nucleus cholecystokinin (CCK   LPBN   ) neurons are a population of glucose-sensing cells (glucose inhibited) with counterregulatory capacity. Furthermore, we reveal that steroidogenic-factor 1 (SF1)-expressing neurons of the ventromedial nucleus of the hypothalamus (SF1 VMH
INTRODUCTION
Due to the serious pathophysiological consequences of low blood glucose, normoglycemia is a tightly defended state regulated by a conserved and coordinated network of peripheral and central systems. Sensory information from peripheral glucosensors is integrated into the wider glucoregulatory/sensory circuitry, defined principally by the brainstem and hypothalamus, which in turn engages the sympathetic nervous system (SNS) and hypothalamic-pituitary-adrenal axis to stimulate glucose production and inhibit glucose uptake (Marty et al., 2007) . Yet, it is unclear how these disparate structures converge to orchestrate sensorimotor responses to dysglycemia.
The lateral parabrachial nucleus (LPBN) forms part of the preautonomic circuitry that subserves physiological responses to numerous viscerosensory modalities, including nociception (Hermanson et al., 1998) , thermostasis (Nakamura and Morrison, 2008) , malaise (Carter et al., 2013) , and energy homeostasis (Wu et al., 2012) . As an assimilatory interoceptive relay for ascending sensory information, the LPBN is therefore neuroanatomically positioned to respond to various aspects of homeostatic dysregulation (Saper, 2002) . Indeed, the LPBN has been implicated in responses to hypoglycemia (Briski, 1999; Fujiwara et al., 1988; Ritter and Dinh, 1994) , but detailed characterization has hitherto been lacking.
RESULTS AND DISCUSSION

CCK
LPBN Neurons Are Responsive to CR-Stimuli The functional diversity of the LPBN is underscored by a complex anatomical substructure and neurochemical composition (Fulwiler and Saper, 1984) . To determine regions of hypoglycemic responsiveness, glucoprivation was pharmacologically induced through administration of the glucose anti-metabolite 2-deoxyglucose (2DG) or insulin (INS) and cFOS-immunoreactivty (IR), a molecular correlate of neuronal activation, assessed across the rostral-caudal extent of the LPBN. Both stimuli increased LPBN cFOS-IR, although the distribution and number of activated neurons was greater upon 2DG administration  Figure S1 available online). Of particular note was the common induction of cFOS-IR within the superior LPBN (sLPBN) . The neuropeptide CCK is highly expressed within the sLPBN (Fulwiler and Saper, 1985) , visualized here using a CCK-ires-Cre::R26-loxSTOPlox-L10-GFP line ( Figures 1F and 1G ). 2DG and INS treatment significantly Figure 2C ) (CNO administration had no effect on blood glucose concentration in the (I and J) CNO treatment did not influence feeding behavior compared to saline. (I) Three hour darkcycle food intake (n = 10; paired t test, t (9) = 0.4, p = 0.7) and (J) 3 hr light-cycle food intake (n = 5; paired t test, t (4) = 1.8, p = 0.1) in ad-libitum-fed mice. CNO, clozapine-N-oxide; G6pc, glucose-6-phosphatase; scp, superior cerebellar peduncle; SAL, saline. All data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Cell Metabolism
VMH Hypoglycemic Counterregulation absence of DREADD-receptor expression; Figure S2C ). Coincident with this rise in blood glucose, CNO administration significantly elevated serum levels of the CR hormones glucagon and corticosterone (Figures 2D and 2E) but had no significant effect on serum INS levels, although there was a trend toward a decrease ( Figure S2D ). Furthermore, CCK LPBN neuron activation also stimulated sympathoexcitatory drive to the adrenal glands, as indicated by increased serum epinephrine levels (Figure 2F) , indicating that these cells couple to the SNS-circuitry requisite for autonomic control of endogenous glucose production. Consistent with these findings, mRNA levels of the glucogenic gene glucose-6-phosphatase (G6pc) increased 2-fold in livers of CNO-treated CCK-ires-Cre::hM3D q -mCherry LPBN mice, compared to saline controls ( Figure 2G ). We next investigated the necessity of CCK neurotransmission for CCK-iresCre::hM3D q -mCherry LPBN -induced hyperglycemia. Systemic pretreatment of CCK-ires-Cre::hM3D q -mCherry LPBN mice with the CCK-receptor antagonist proglumide abrogated the previously observed elevation in blood glucose ( Figure 2H ), revealing that LPBN-derived CCK is the functionally relevant neurotransmitter in this physiological context. These data demonstrate that the CCK LPBN neurons, and specifically CCK neuropeptide, are sufficient to drive CR-like responses. Interestingly, despite the involvement of both the LPBN (Wu et al., 2012) and CCK (Little et al., 2005) Figure 3D ). Similarly, under INS-induced hypoglycemia, CCK LPBN neuron silencing engendered an exaggerated hypoglycemic response that impaired re-establishment of normoglycemia ( Figure 3E ). Thus, CCK LPBN neurons form part of the neurocircuitry underlying centrally regulated glycemia and are both necessary and sufficient for CR-responses to glucoprivation. CCK LPBN neuron silencing did not affect feeding behavior (Figures S3A-S3C) .
To probe the neurocircuit underlying CCK LPBN neuron-mediated glucoregulation, their specific efferent targets were assessed using genetically encoded neuronal tract-tracing. Unilateral viral transduction of CCK LPBN neurons with Cre-dependent synaptophysin-mCherry revealed a strictly ascending projection profile, with terminals concentrated predominantly within the ipsilateral hypothalamus ( Figures 4A-4C and S4A-S4F). The densest site of CCK LPBN neuron innervation was the ventromedial nucleus of the hypothalamus (VMH), and in particular the dorsomedial compartment (dmVMH) ( Figure 4C ). This robust innervation, together with the well-established glucoregulatory capacity and preautonomic function of the VMH (Borg et al., 1994; Borg et al., 1995; Choi et al., 2013) , supported its role as a site of functional outflow for CR CCK LPBN neurons.
SF1 is required for the terminal differentiation of the VMH and is expressed predominantly in the dmVMH of adult mice (Choi et al., 2013) . Conditional genetic manipulations have demonstrated that SF1 neurons are required for CR-response to hypoglycemia (Kim et al., 2012; Klö ckener et al., 2011; Tong et al., 2007 Figure 4D ). Consistent with this observation and the excitatory effect of CCK on the VMH (Kow and Pfaff, 1986) , electrophysiological recordings from synaptically isolated SF1 VMH neurons at low (0.5 mM) and normal (5 mM) glucose conditions revealed that 55% (5/9) were stimulated by exogenous CCK, with responding cells increasing their firing rate 2. Figures S4H and S4I) . In light of evidence that LPBN-derived CCK is the sole source of CCK terminals within the VMH (Nagai et al., 1987) , these data suggest SF1 VMH neuron responsiveness to CCK lies in their innervation by CCK LPBN neurons. Furthermore, the robustly glutamatergic nature of the LPBN led us to consider the potential contribution of fast neurotransmission from CCK LPBN neurons.
Interestingly, we did not observe VMH projections from glutamatergic vGLUT2 LPBN neurons ( Figure S4J ), and vGLUT2-iresCre::hM3Dq-mCherry LPBN stimulation failed to elevate blood glucose levels ( Figure S4K ). These data suggest that VMH-projecting CCK LPBN neurons are not glutamatergic and support our observation that CCK receptor blockade is sufficient to abrogate the hyperglycemic response to CNO in CCK-iresCre::hM3Dq-mCherry LPBN mice ( Figure 2H ). Taking advantage of the spatial exclusivity of CCK and SF1 expression in the LPBN and VMH, respectively, we next generated compound CCK-ires-Cre::SF1-Cre mice to facilitate neurochemically explicit manipulation of this CCK LPBN /SF1 Figure 4H ). Silencing of SF1 VMH neurons alone had no effect on blood glucose concentration, indicating a causal interaction between these two populations, and not simply a counteracting additive effect ( Figure 4I ). Furthermore, like CCK LPBN neurons, silencing of SF1 VMH cells within the context of 2DG-glucoprivation induced an attenuated CR-response ( Figure S4L) . Control experiments performed to rule out any contribution from CCK neurons within the dorsomedial nucleus of the hypothalamus, compact part (cDMH), which neighbors the SF1 VMH domain, revealed that CCK cDMH neurons had neither any effect on blood glucose levels nor were engaged by glucoregulatory CCK LPBN neurons ( Figures S4M-S4P ). These data suggest that the CR function of CCK LPBN neurons is predicated upon their engagement of downstream SF1 VMH neurons. Interestingly, systemic antagonism of CCK B -receptors, the predominant central receptor isoform (and enriched in the dmVMH), was sufficient to significantly attenuate the hyperglycemic response to 2DG in wild-type mice ( Figure 4J ), highlighting the salience of CCK B -receptor signaling to CR-responses, although not definitively identifying specific receptor-expressing neuronal populations.
(I) SF1 VMH neuron silencing does not influence blood glucose concentrations compared to saline (n = 4; repeated-measures ANOVA; main effects of treatment, time, and interaction not significant).
(J) The CR-response to 2DG was significantly attenuated by pretreatment with the selective CCK B -receptor antagonist CI988 (n = 5 per group; two-way ANOVA; main effect of treatment [F (3,112) (Choi et al., 2013; Kim et al., 2012; Tong et al., 2007) . In sum, the present study defines the physiological function of a discrete CCK LPBN /SF1 VMH microcircuit that drives hepatic glucose production and mediates CR responses to hypoglycemia. Furthermore, these data identify a critical function for CCK in the physiological response to glucoprivation. These observations have salience to both homeostatic function in health and dysregulation in disease, in particular diabetes.
EXPERIMENTAL PROCEDURES
Animals CCK-ires-Cre (Jackson Laboratories), SF1-Cre, vGLUT2-ires-Cre, and R26-loxSTOPlox-L10-GFP mice were generated and maintained as previously described (Dhillon et al., 2006; Krashes et al., 2014; Taniguchi et al., 2011) . Animal care and experimental procedures were performed with approval by the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee or were performed in accordance with the UK Animals (Scientific Procedures) Act 1986.
Viruses
The DREADD viruses used have been described previously: AAV8-hSyn-DIOhM3D q -mCherry and AAV8-hSyn-DIO-hM4D i -mCherry (University North Carolina Vector Core) (Krashes et al., 2011) . A Cre-dependent expression cassette for hEF1alpha-DIO-synaptophysin-mCherry-WPRE (Opland et al., 2013) was generated (MIT Viral Gene Transfer Core) and the construct packaged in AAV serotype-8 at a titer of 1.3 3 10 13 vg/ml (Virovek, Inc). Nucleus specific delivery of viruses was achieved through stereotaxic delivery based upon coordinates defined by the Mouse Brain Atlas (Franklin and Paxinos, 2008 ).
Blood Glucose Studies
On test days, mice were transferred to new cages and food removed at 9:00 am. Mice remained fasted until 1:00 pm, when the experiment would commence. Blood glucose concentration was determined by tail bleed using a OneTouch Ultra glucometer and test strips (LifeScan, Johnson and Johnson Company) . Basal blood glucose concentration was determined prior to injection of any substances and at 15, 30, 60, 120, and 180 min postadministration. Pretreatments were given 30 min prior to pharmacological stimulus. Experiments were within study design (unless otherwise stated), with mice assessed following saline and 1 mg/kg CNO. Animals undergoing loss-of-function experiments involving glucoprivic stimuli (INS or 2DG) were counterbalanced and given 3 weeks recovery time between treatments to ensure normal counterregulatory responses were intact.
Immunohistochemistry
Brains were sectioned on a freezing microtome at 30 mm. Dual immunofluorescence histochemistry for cFOS-IR, mCherry-IR, and GFP-IR was conducted as previously described (Garfield et al., 2012) . Primary antibodies (1/1,000) were as follows: rabbit anti-cFOS (EMD Millipore), rabbit anti-RFP (Clontech Laboratories, Inc.), or chicken anti-GFP (EMD Millipore).
Serum and Tissue Extraction
For assessment of serum chemistry and hepatic gene expression animals were decapitated, and fresh trunk blood and liver samples were collected. Blood was collected in tubes containing 250 KIU/ml aprotinin (EMD Millipore), allowed to coagulate at room temperature for 30 min, centrifuged at 1,500 3 g for 10 min, and the resulting serum transferred to a new tube. Samples were flash frozen in liquid nitrogen and kept at À80 C until analyzed. Liver extracts were flash frozen in liquid nitrogen and kept at À80 C until RNA was extracted.
Electrophysiological Studies
To assess the effects of CNO on CCK LPBN neurons, 5-to 7-week-old CCKires-Cre mice were injected with either AAV8-DIO-hM3D q -mCherry or AAV8-DIO-hM4D i -mCherry into the LPBN 3 weeks before recording. Slices were maintained in aCSF containing 10 mM glucose. After acquisition of stable, whole-cell recordings for 2 to 5 min, aCSF solution containing CNO (5 mM) was perfused into the brain slice preparation (for hM4Di-mCherry analysis, cells were injected with 5 pA of current). To assess the effect of CCK on VMH neurons (SF1+ or SFÀ neurons), 6-to 8-weeks-old SF1-Cre::R26-loxSTOPlox-L10-GFP mice were used. CCK-8S (100 nM; Tocris Biosciences) and CI988 (500 nM; Tocris Biosciences) were applied to bath solution containing either 5 mM or 0.5 mM glucose through perfusion. After acquisition of stable, whole-cell recording for 2-5 min, acSF solution containing 100 nM of CCK-8S was perfused for 3 to 5 min. Synaptic blockers (1 mM kynurenate and 100 mM picrotoxin) were added in aCSF to synaptically isolate VMH neurons. The effect of glucose concentration on CCK LPBN neuron activity was assessed using a 5 mM/0.5 mM/5 mM step protocol, with osmolarity adjusted with sucrose.
Statistics
Statistical analyses were performed using Prism 6 (Graphpad Software, Inc). Data were analyzed using t test, one-way ANOVA, or two-way ANOVA with post hoc comparisons, where appropriate. Data are presented as mean ± SEM, and statistical significance was set at p < 0.05
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